Drug Eluting Balloons - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

Drug eluting balloons market size in 2026 is estimated at USD 853.75 million, growing from 2025 value of USD 0.79 billion with 2031 projections showing USD 1.26 billion, growing at 8.07% CAGR over 2026-2031. This report is Segmented by Product (Coronary Drug-Eluting Balloon, Peripheral Drug-Eluting Balloon, Other Products), Drug Type (Paclitaxel-Based Balloons, and More), Coating Technology (FreePac, Transpac, and More), Lesion Type (In-Stent Restenosis, and More), End User (Hospitals, and More), and Geography (North America, Europe, and More). The Market Forecasts are Provided in Terms of Value (USD).

Global Drug Eluting Balloons Market Trends and Insights

Growing Prevalence of Peripheral & Coronary Artery Diseases

Ischemic heart disease remains the leading source of age-standardized disability worldwide, and absolute case volumes keep rising because population growth offsets mortality gains. As multi-vessel disease burdens older, more-comorbid patients, clinicians require revascularization modalities that minimize vessel trauma and shorten pharmacotherapy. Drug eluting balloon market adoption benefits because DEBs deliver antiproliferative drugs without leaving metal scaffolds, reducing repeat-intervention risk in tortuous or heavily calcified segments. BTK disease, historically underserved, sees particular gains as DEBs demonstrate limb-salvage advantages over plain angioplasty.

Rising Geriatric Population & Cardiovascular Risk

Patients ≥65 years now represent the fastest-growing cohort undergoing percutaneous interventions, yet they carry heightened bleeding risk and intolerance to prolonged dual antiplatelet regimens. DEBs allow local drug delivery without permanent implants, enabling shorter antiplatelet courses that align with geriatric safety priorities. Japan’s 2023 consensus endorsing coronary DEBs illustrates how rapidly ageing regions legitimize stent-free approaches. Because seniors often present calcified and tortuous anatomy, the device’s low-profile crossing ability further drives drug eluting balloon market utilisation in this demographic.

High Cost of R&D and Commercialization

Drug-eluting balloon development requires substantial investment in clinical trials, regulatory submissions, and manufacturing infrastructure that creates barriers to market entry and limits competitive intensity. It further requires toxicology work and purpose-built coating facilities that can push development budgets beyond USD 100 million, limiting new entrants. Comparative-effectiveness mandates versus legacy stents add further cost, elevating break-even thresholds and slowing portfolio diversification. Smaller firms often license or sell assets to majors, concentrating intellectual property and tempering price competition within the drug-eluting balloon market. Downstream, premium prices impede penetration in cost-sensitive systems despite clinical need.

Other drivers and restraints analyzed in the detailed report include:

• Increasing Adoption of Sirolimus-Coated Balloon Platforms
• Emerging Clinical Data Supporting De-Novo Small-Vessel PCI Use
• Safety Concerns Over Paclitaxel Mortality Signal

Segment Analysis

Peripheral drug-eluting balloons command 58.30% market share in 2025, reflecting their established clinical utility in femoropopliteal and below-the-knee applications where stent placement faces mechanical challenges from vessel movement and external compression. The SELUTION SFA Japan trial's demonstration of 87.9% primary patency at 12 months reinforces peripheral drug-coated balloon efficacy in challenging anatomical territories. Peripheral procedures retain a larger installed base because early paclitaxel devices debuted in femoropopliteal lesions, creating clinician familiarity. Yet the coronary pipeline, supported by expanded de-novo and small-vessel evidence, should narrow the revenue gap as reimbursement hurdles fall.

Coronary drug-eluting balloons show the highest growth trajectory at 9.65% CAGR through 2031, driven by expanding clinical evidence and recent FDA approvals that legitimize their use in coronary in-stent restenosis and small vessel disease. Other products including renal and urology applications represent emerging opportunities, with Abbott's Esprit BTK system approval in April 2024 demonstrating regulatory support for specialized anatomical applications.

The transition toward sirolimus-based formulations accelerates at 9.32% CAGR through 2031, challenging paclitaxel's 78.45% market share in 2025 as clinicians seek alternatives with improved safety profiles and broader therapeutic windows. Cordis's USD 1.1 billion acquisition of MedAlliance brought SELUTION SLR technology, utilizing proprietary MicroReservoir drug delivery for sustained sirolimus release.

Dual-drug and novel agent formulations represent experimental approaches that may address limitations of single-agent platforms, though clinical evidence remains limited. Paclitaxel maintains dominance through established clinical data and manufacturing scale, yet safety concerns following recent mortality signals continue influencing physician preferences despite FDA guidance clearing excess mortality risk.

Complete Report Scope:

• By Product
  • Coronary Drug-eluting Balloon
  • Peripheral Drug-eluting Balloon
  • Other Products (Renal/Urology)
• By Drug Type
  • Paclitaxel-based Balloons
  • Sirolimus-based Balloons
  • Dual-drug / Novel Agents
• By Coating Technology
  • FreePac
  • TransPac
  • EnduraCoat
  • Other Technologies
• By Lesion Type
  • In-stent Restenosis
  • De-novo Small Vessel Disease
  • Femoropopliteal Lesions
  • Below-the-knee Lesions
• By End User
  • Hospitals
  • Ambulatory Surgical Centers
  • Other End Users
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America generated 42.10% of 2025 revenue following the FDA’s landmark coronary DEB approval and CMS pass-through payment creation, which together eliminated twin adoption barriers. The presence of leading manufacturers, extensive trial infrastructure, and established ASC networks underpin steady but moderate future growth.

Europe maintains entrenched clinical know-how yet faces stricter paclitaxel surveillance that may temper volumes until sirolimus platforms scale. Germany and Italy remain procedural leaders, while budget-conscious systems in Southern Europe weigh DEB cost-utility versus modern stents.

Asia-Pacific is projected to post the highest 10.05% CAGR as ageing demographics intersect with rapid cath-lab expansion. Japan’s national consensus endorsing broader coronary use, China’s expedited approvals, and India’s rising middle-class demand together create fertile ground for the drug eluting balloon market. Regional manufacturers such as MicroPort bolster domestic supply and stimulate price competition that accelerates penetration. Middle East & Africa and South America together deliver smaller baselines but show selective strength in Gulf Cooperation Council states and Brazil, respectively. Infrastructure upgrades and private-sector cardiovascular centres widen access, yet reimbursement lags and currency volatility moderate the near-term trajectory.

List of Companies Covered in this Report:

• Medtronic
• Boston Scientific
• Beckton Dickinson
• Terumo
• Koninklijke Philips
• Cook Group
• BIOTRONIK
• B. Braun
• Surmodics, Inc.
• Abbott Laboratories
• Concept Medical
• Cardionovum
• Eurocor GmbH
• Lepu Medical
• iVascular S.L.U
• Alvimedica
• Opto Circuits (India) Ltd.
• Shenzhen MicroPort CardioFlow Medtech
• AngioDynamics
• Paladin Medical

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support